Bicycle Therapeutics (BCYC) stock price, revenue, and financials

Bicycle Therapeutics market cap is $971.9 m, and annual revenue was $10.39 m in FY 2020

$971.9 M

BCYC Mkt cap, 14-Sept-2021

$1.8 M

Bicycle Therapeutics Revenue Q1, 2021
Bicycle Therapeutics Net income (Q1, 2021)-16.2 M
Bicycle Therapeutics EBIT (Q1, 2021)-16 M
Bicycle Therapeutics Cash, 31-Mar-2021195.9 M
Bicycle Therapeutics EV808.6 M
Get notified regarding key financial metrics and revenue changes at Bicycle TherapeuticsLearn more
Banner background

Bicycle Therapeutics Revenue Breakdown

Embed Graph

Bicycle Therapeutics revenue breakdown by business segment: 24.4% from Oxurion Agreement, 56.2% from Bioverativ Agreement and 19.4% from AstraZeneca Agreement

Bicycle Therapeutics Income Statement

Annual

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

836.1k81.1k45.0k2.1m7.1m13.8m10.4m

Revenue growth, %

246%

R&D expense

11.9m70.8m25.5m33.1m

General and administrative expense

6.4m8.1m14.6m29.2m

Operating expense total

3.0m3.6m8.3m18.3m78.9m40.1m62.4m

EBITDA

(2.3m)(2.0m)(3.4m)(8.0m)

EBITDA margin, %

(236%)(4158%)(17856%)

EBIT

(2.4m)(2.1m)(3.5m)(8.2m)(16.2m)(21.7m)(26.3m)(52.0m)

EBIT margin, %

(254%)(4371%)(18300%)(787%)(305%)(191%)(500%)

Interest income

814.0k683.0k

Pre tax profit

(2.5m)(2.1m)(3.5m)(8.2m)(16.3m)(22.2m)(30.9m)(51.7m)

Income tax expense

331.6k456.0k599.3k1.5m(23.0k)(396.0k)(300.0k)(724.0k)

Net Income

(2.1m)(1.7m)(2.9m)(6.7m)(16.3m)(21.8m)(30.6m)(51.0m)

Quarterly

USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020Q1, 2021

Revenue

1.5m614.0k1.6m3.8m1.8m

R&D expense

6.5m6.1m8.0m7.4m9.7m

General and administrative expense

3.0m4.8m6.2m7.2m8.1m

Operating expense total

9.5m10.9m14.2m14.5m17.8m

EBIT

(8.0m)(10.3m)(12.6m)(10.7m)(16.0m)

EBIT margin, %

(525%)(1670%)(801%)(278%)(886%)

Interest expense

2.1m440.0k

Interest income

90.0k440.0k371.0k72.0k15.0k

Pre tax profit

(10.1m)(9.8m)(12.2m)(10.6m)(16.5m)

Income tax expense

135.0k(331.0k)(97.0k)(500.0k)(300.0k)

Net Income

(10.2m)(9.5m)(12.1m)(10.1m)(16.2m)

Bicycle Therapeutics Balance Sheet

Annual

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

2.3m451.3k5.4m6.5m67.7m63.4m

Accounts Receivable

5.0m201.0k5.5m

Prepaid Expenses

848.0k2.1m4.9m5.1m

Current Assets

2.7m989.3k6.2m8.3m71.5m76.8m104.1m155.7m

PP&E

381.1k395.2k487.2k474.0k1.4m1.8m2.3m2.3m

Total Assets

3.2m1.6m6.8m9.0m74.0m81.6m110.2m161.2m

Accounts Payable

185.4k142.2k195.6k307.0k2.1m1.9m1.9m1.4m

Current Liabilities

339.6k308.1k405.9k1.1m9.5m8.9m8.8m23.1m

Long-term debt

1.3m14.9m

Total Debt

1.3m14.9m

Total Liabilities

339.6k308.1k405.9k1.1m24.7m29.3m17.0m65.7m

Common Stock

9.4k9.7k18.1k26.0k4.0k8.0k227.0k266.0k

Preferred Stock

96.4m122.2m

Additional Paid-in Capital

9.4k9.7k18.1k26.0k839.0k1.9m195.1m249.9m

Retained Earnings

(4.7m)(6.3m)(9.3m)(16.0m)(48.1m)(69.9m)(100.5m)(151.6m)

Total Equity

2.9m1.2m6.4m7.9m49.3m52.4m93.2m95.5m

Financial Leverage

1.1 x1.2 x1.1 x1.1 x1.5 x1.6 x1.2 x1.7 x

Bicycle Therapeutics Cash Flow

Annual

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.1m)(1.7m)(2.9m)(6.7m)(16.3m)(21.8m)(30.6m)(51.0m)

Depreciation and Amortization

332.0k712.0k960.0k1.3m

Accounts Receivable

(400.0k)4.9m(2.1m)

Accounts Payable

67.0k(169.0k)220.0k(663.0k)

Cash From Operating Activities

(1.4m)(26.1m)(28.6m)(17.8m)

Purchases of PP&E

(1.1m)(1.2m)(1.6m)(1.2m)

Cash From Investing Activities

(1.1m)(1.2m)(1.6m)(1.2m)

Cash From Financing Activities

57.9m25.4m58.4m62.8m

Net Change in Cash

58.3m(4.3m)28.7m43.9m

Interest Paid

378.0k

Income Taxes Paid

73.0k117.0k124.0k

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(16.7m)(26.2m)(11.3m)(23.4m)(33.6m)(16.2m)

Depreciation and Amortization

443.0k686.0k305.0k615.0k944.0k325.0k

Accounts Receivable

5.0m5.1m(846.0k)(332.0k)(2.7m)3.5m

Accounts Payable

530.0k516.0k2.7m1.3m193.0k(304.0k)

Cash From Operating Activities

(12.8m)(23.7m)21.2m8.8m(1.2m)(13.7m)

Purchases of PP&E

(881.0k)(1.2m)(320.0k)(621.0k)(716.0k)(623.0k)

Cash From Investing Activities

(881.0k)(1.2m)(320.0k)(621.0k)(716.0k)(623.0k)

Cash From Financing Activities

59.1m58.3m2.0k12.0k61.1m74.1m

Net Change in Cash

45.2m32.6m17.5m4.8m57.7m59.9m

Interest Paid

429.0k

Income Taxes Paid

73.0k73.0k11.0k38.0k124.0k

Bicycle Therapeutics Ratios

USDFY, 2013

Financial Leverage

1.1 x